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Abstract: Norfloxacin is a poorly water soluble drug, and to improve its solubility it was complexed with b-cyclodextrin (BCD).
Several ocular patches/inserts of norfloxacin-b-cyclodextrin were prepared in hydroxypropyl methyl cellulose (HPMC) matrix. The
influence of rate controlling membranes made of ethyl cellulose (EC) alone and in combination with polyvinyl pyrrolidone K30 (PVP
K30) in different proportions on drug release kinetics was studied. The data were subjected to regression analysis. Various physical
characteristics of the films were evaluated. In vitro release studies were carried out in a fabricated flow through cell. All the films
prepared were found to be uniform in thickness, and the partition coefficient of norfloxacin and its betacyclodextrin complex was
0.048 and 0.853, respectively. I.R. spectra revealed complexation of norfloxacin with b-cyclodextrin. In vitro results revealed that
2 patch/insert formulations, V1 and V2, followed perfect zero order kinetics release (n = 1), and 3 formulations, V3, V4 and V5,
released the drug by super case II kinetics (n > 1). The study confirmed the improved solubility of norfloxacin when complexed with
b-cyclodextrin and that it can be delivered through films made of HPMC matrix cast with EC alone or with a combination of PVP
K30. It was also observed that increasing the proportion of PVP K30 into EC increased the rate of release of norfloxacin.
Key Words: Ocular insert, norfloxacin, beta-cyclodextrins.

The eye as a portal for drug delivery is generally used
for local therapy against systemic therapy in order to
avoid the risk of eye damage from high blood
concentrations of the drug, which is not intended. The
unique anatomy, physiology and biochemistry of the eye
render this organ impervious to foreign substances, thus
presenting a constant challenge to the formulator to
circumvent the protective barriers of the eye without
causing permanent tissue damage.

precorneal cavity by constant tear flow and lacrimo-nasal
drainage. Therefore only a very small fraction of the
instilled dose is absorbed by the target tissue for this
reason, concentrated solutions and frequent dosing are
required for the instillation to achieve an adequate level
of therapeutic effect (1). One of the new classes of drug
delivery systems, polymeric film ocular drug delivery
systems, which are gaining worldwide accolade, release
drugs at a pre-programmed rate for a longer period by
increasing the precorneal residence time.

Most ocular treatments like eye drops and
suspensions call for the topical administration of
ophthalmically active drugs to the tissues around the
ocular cavity. These dosage forms are easy to instill but
suffer from the inherent drawback that the majority of
the medication they contain is immediately diluted in the
tear film as soon as the eye drop solution is instilled into
the cul-de-sac and is rapidly drained away from the

Norfloxacin is a hydrophobic broad spectrum
antibacterial with a half-life of 3 to 4.5 h frequently used
in ocular infections, and is insoluble in water (2). There
are only a few ocular inserts available on the market,
made of ethylene vinylacetate (EVA) (3-5) as a rate
controlling membrane. Likewise, ethyl cellulose (EC) is
also an excellent film-forming polymer but the films of EC
alone are brittle. It offers more resistance to the diffusion
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of drug molecules, and is less explored as a polymer for
ocular delivery of drugs. The current literature indicates
that none are made of hydrophilic monolithic systems
containing norfloxacin. Hence this investigation was taken
up to study the drug release kinetics of norfloxacin from
a hydrophilic, monolithic reservoir system of HPMC cast
with rate controlling membranes made of EC and PVP
K30. With the addition of PVP K30 to EC, the films of EC
become resilient and do not break easily and it was
ascertained that the drug diffusion might improve (6-11).
It was aimed to prepare ocular films containing
norfloxacin with better solubility and longer duration of
action delivering the drug in zero order kinetics.

buffer saline (IPBS) of pH 7.4 was prepared in distilled
water.

Since the drug has poor aqueous solubility it was
required to modify the solubility characteristics of
norfloxacin. Therefore in this work an attempt was made
to improve the solubility of the norfloxacin by forming an
inclusion complex with β-cyclodextrin (BCD). Hydroxy
propyl methyl cellulose (HPMC) and polyvinyl pyrrolidineK30 (PVP K30) are hydrophilic polymers whereas EC is a
hydrophobic polymer and all these polymers show
excellent film forming ability. It was also considered to
modify the characteristics of EC. Hence, in this
investigation the complex dispersed in HPMC matrix was
cast with rate controlling membranes made of either EC
alone, or in combination with PVP K30. The effect of
ethyl cellulose polymer as a rate controlling membrane
alone and in different combinations with PVP K30, i.e.
EC:PVP K30; 8:1; 4:1; 2:1 and 1:1 ratios, on drug
release kinetics was investigated.

where Cs = concentration of the drug present in the
matrix, k = rate constant and t = time. Since Cs is a
constant, and x = amount of drug released described as

Materials and Methods
Norfloxacin (NOR) was obtained as a complimentary
sample from Torrent Pharmaceuticals, Mumbai, and
betacyclodextrin (BCD) from Sun Pharma Limited,
Ahmednagar. Hydroxy propyl methyl cellulose (HPMC),
ethyl cellulose (EC), and polyvinyl pyrrolidone K30 were
all from the Central Drugs House, Mumbai. Glycerol and
dibutyl phthalate (DBP) were from Qualigens Fine
Chemicals, Mumbai.
In the present work, norfloxacin was estimated using
a double beam UV spectrophotometer (Hitachi U-2000,
Japan) at 272.5 nm. The formation of complexation
between norfloxacin and β-cyclodextrin by neutralization,
was studied by Fourier transform–infra red spectroscopy
(Model Shimadzu FTIR 8000 series). Isotonic phosphate
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The in vitro data were analyzed by a zero order
kinetics equation as well as Korsemeyer’s equation (12)
to understand the release profile and release mechanism.
When a graph of the cumulative percentage of the drug
released from the matrix against time is plotted, zero
order release is linear in such a plot, indicating that the
release rate is independent of concentration. The rate of
release of the drug can be described mathematically as
follows:
Rate of release = (dCs/t) = k

dx / dt = k integration of the equation yields
x = k t + constant
A plot of x versus t results in a straight line with the
slope = k. The value of k indicates the amount of the drug
released per unit of time and the intercept of the line at
time zero is equal to the constant in the equation. The
curves plotted may have different slopes, and hence it
becomes difficult to exactly pinpoint which curve follows
perfect zero order release kinetics. Therefore, to confirm
the kinetics of drug release, in vitro data were also
analyzed using Korsemeyer’s equation.
Korsemeyer et al. used a simple empirical equation to
describe general solute release behavior from controlled
release polymer matrices:
mt/m∞ = k * tn
where mt/m∞ = fraction of drug released, k = kinetic
constant, t = release time and n = the diffusional
exponent for drug release.
The slope of the linear curve gives the ‘n’ value.
Peppas stated that the above equation could adequately
describe the release of solutes from slabs, spheres,
cylinders and discs, regardless of the release mechanism.
The value of ‘n’ gives an indication of the release
mechanism. When n = 1, the release rate is independent
of time (zero order) (case II transport); n = 0.5 for
Fickian diffusion; and when 0.5 < n < 1, diffusion and
non-Fickian transport are implicated. Lastly, when n >
1.0 super case II transport is apparent. ‘n’ is the slope
value of log mt/m∞ versus log time curve.
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Preparation of inclusion complex by neutralization
method (13)
Norfloxacin (NOR) and β-cyclodextrin (BCD) in a
molar ratio of 1:1 were separately dissolved in 0.1 N
NaOH, mixed and stirred for half an hour. 0.1 N HCl was
added to this solution dropwise until the solution attained
pH 7.5, when the complex precipitated. The precipitate
was washed with distilled water until it was free of
chloride ions.
The monolithic drug reservoir patches were prepared
from aqueous solutions of HPMC with inclusion complex
of BCD containing norfloxacin. The films were cast by the
mercury substrate method (14). A Teflon ring was placed
in a pool of mercury, and then the matrix solution
containing the drug was loaded onto this ring. It was
allowed to dry uniformly under ambient conditions. An
area of 0.502 cm2 containing 2 mg of norfloxacin was
used for all the studies.

Preparation of rate controlling membranes
The rate controlling membranes were prepared from
EC alone (V1) and also with EC: PVP K30 in different
proportions. Four different proportions of EC:PVP K30
were modeled, i.e. 8:1(V2), 4:1(V3), 2:1(V4) and 1:1
(V5) ratios. Weighed quantities of the polymers or their
ratios were solubilized in distilled water with continuous
mixing. The matrix solution such prepared was pipetted
and poured onto a Teflon ring placed in a mercury pool.
The matrix was dried constantly under ambient
conditions. In all the films dibutyl phthalate (DBP) 15%
w/w was incorporated as a plasticizer.

The aqueous phase was assayed before and after
partitioning, using a UV spectrophotometer to get the
partition coefficient. Triplicate readings were taken and
the average was calculated. A similar experiment was
carried out with an equivalent amount of NOR-BCD
complex. In vitro diffusion studies were performed in a
fabricated flow through assembly using IPBS 7.4 as
media. Norfloxacin was extracted from the film into a
solution of IPBS 7.4 and after extracting the drug for 24
h the drug content was determined. The average of
triplicate readings was taken. Films of 0.502 cm2 in area
were used from each formulation.

Description of open flow through assembly
(16,17)
Since there was no specific official method prescribed
for in vitro studies of ocular film/inserts, we fabricated an
open flow through assembly, simulating the conditions of
the ocular cavity, in our laboratory for the purpose of this
investigation (Figure 1).
A 2 ml glass tube open at both ends was used as an in
vitro diffusion cell. Two fluted glass adapters were fused
at both open ends so that one formed the inlet and the
other fluted end was used to withdraw samples. The inlet

CONSTANT HEAD RESERVOIR
CONTAINING BUFFER

Evaluation of ocular films:
The above films were evaluated for the thickness of
each film using a micrometer of sensitivity of 0.001 mm
(Mitutoyo, Japan). The average of 10 readings was
taken. The mean thickness, standard deviation and
percent coefficient of variation were calculated. The
octanol:water partition coefficient (15) was determined
for the drug and also its complex with BCD. A drug
solution of 50 µg/ml was prepared in distilled water and
25 ml of this solution was taken in a separating funnel
and shaken with an equal volume of octanol for 10 min
and allowed to stand for 1 h. Then the aqueous phase
was separated, and centrifuged for 10 min at 2000 rpm.

CONDUIT

CONTROL
VALVE

Figure 1. Schematic diagram of open flow through assembly.
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end of this tube was connected to a reservoir containing
IPBS pH 7.4. The head of the reservoir was kept
constant. Flexible PVC tubing was connected from this
reservoir to the cell, in which 2 ml of buffer was
maintained constant. The rate of flow of buffer was
controlled with a valve and adjusted to 0.166 ml/min.
Taking 25 readings initially, the setup was validated and
the standard deviation (0.166 ± 0.03 ml) and percent
coefficient of variation were observed to be minimum;
hence, the setup was used throughout the work.
IPBS pH 7.4 was put into the reservoir. A small
volume of fluid was allowed to drain away, so as to
remove any entrapped air bubbles in the cell. An ocular
patch was stuck onto a thin small, circular, teflon disc, so
that only one surface was exposed to the diffusion fluid.
This disc was steadily inserted into the cell containing 2
ml of fluid. The temperature of the fluid was kept at 35
± 1 °C constantly. At regular intervals the diffusion fluid
was taken to analyze for drug content using a UV
spectrophotometer. Simultaneously a blank was
performed under similar conditions as described, with a
drug devoid film. Triplicate readings were taken and the
average was calculated and tabulated.

Results and Discussion
The drug content in each film formulation was found
to be almost the same as for theoretical norfloxacin (2
mg) added to the monolithic film (Table 1). The thickness
of the patches was fairly uniform and consistent, as
indicated by their low standard deviations (Table 2). The
partition coefficient was 0.048 and 0.853 for pure drug
and the NOR-BCD complex, respectively, indicating a fair
increase in the aqueous solubility of the drug. Figures 2
and 3 represent the IR spectra of norfloxacin and its BCD
complex, respectively. The spectrum of norfloxacin shows
an absorption band for C = O at 1730 cm-1 as the fraction
of the –COOH group, whereas the IR spectra of the
complex does not show any absorption band in that
region, i.e. 1650 cm-1 to 1750 cm-1. This clearly indicated
that the complex between the norfloxacin and βcyclodextrin is formed via the C = O group of norfloxacin
and the hydrogen of the secondary hydroxyl group of the
β-cyclodextrin. The IR spectrum of the norfloxacin shows
a sharp peak at 2400 cm-1, which indicates only one –OH
group.
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Table 1. Drug content of norfloxacin.
Formulation

Actual amount of drug

% Drug content*

V1
V2
V3
V4
V5

1.9481
1.9446
1.9298
1.9334
1.9372

97.41
97.23
96.49
96.67
96.86

* → Average of 3 readings

Table 2.

Formulae

V1
V2
V3
V4
V5

Thickness, slopes and regression values of zero order and
Korsemeyer models.
Thickness* (µm)

71.1 ± .0037
71.0 ± 0.0030
73.3 ± 0.0050
74.1 ± 0.0044
75.8 ± 0.0034

Zero order

Korsemeyer

k

r

n

r

0.4199
0.4897
0.7284
0.8170
0.9224

0.988
0.978
0.999
0.979
0.978

1.00
1.00
1.10
1.11
1.15

0.986
0.979
0.977
0.950
0.961

* → Average of 10 readings

In vitro release studies
The basic in vitro data obtained are tabulated in Table
3. Initially the drug release from the HPMC matrix film
containing drug complex was studied. The study showed
first order release kinetics with a rate constant of
3.983*10-3 (r = 0.9476); nearly 90% of the drug was
released within 3 h. This means that the film is to be
applied several times a day to the conjunctiva. Therefore,
to reduce frequency of administration and to control the
drug release for several days, further films, with EC and
PVP K30, were prepared in different ratios. In controlled
drug delivery zero order is the most preferred kinetics of
drug release. Therefore films of EC were modeled to
release the drug in zero order mode. The zero order plots
of V1, V2, V3, V4 and V5 were found to be fairly linear,
as indicated by their high regressional value (Figure 4).
Therefore, it was ascertained that the drug release from
V1, V2, V3, V4 and V5 could follow either near zero or
zero order kinetics. The zero order curves alone are not
sufficient to predict zero order since each curve, albeit
straight, has a different slope. Hence to confirm the exact
mechanism of drug release from the films, the data were
computed and graphed according to Korsemeyer’s
equation, as shown in Figure 5. Regression analysis was
performed (18) and the regression value ‘r’ suggested
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Figure 2. I.R. spectra of norfloxacin.
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Figure 3. IR spectra of norfloxacin- ß-cyclodextrin complex.
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Table 3. In vitro release data of V1, V2, V3, V4 and V5.
Time
(h)

Log
time

Cum%
drug
release

Log
mt/m∞
x 103

Cum%
drug
release

Log
mt/m∞
x 103

Cum%
drug
release

Log
mt/m∞
x 103

Cum%
drug
release

Log
mt/m∞
x 103

Cum%
drug
release

Log
mt/m∞
x 103

0
0.5
1
2
4
8
12
24
36
48
60
72
84
96
108
120
132
144
156
168
180
192
204
216
228

0.0000
-0.3010
0.0000
0.3010
0.6020
0.9030
1.0791
1.3802
1.5563
1.6812
1.7781
1.8573
1.9242
1.9822
2.0334
2.0791
2.1205
2.1583
2.1931
2.2253
2.2552
2.2833
2.3093
2.3344
2.3579

0.00
0.18
0.39
0.84
2.00
5.05
7.91
12.90
18.75
25.65
33.62
39.05
46.30
51.82
57.52
61.89
65.68
69.68
72.80
76.03
78.86
82.32
85.25
87.47
89.86

0.00
0.307
0.642
0.974
1.348
1.750
1.953
2.157
2.319
2.455
2.573
2.638
2.712
2.760
2.806
2.838
2.865
2.889
2.908
2.927
2.943
2.961
2.977
2.988
3.000

0.00
0.28
0.62
1.18
3.22
6.62
8.53
13.38
20.66
28.25
34.07
41.40
57.12
65.70
70.68
73.78
76.41
79.10
81.14
83.60
85.45
85.70
90.73

0.00
0.477
0.778
1.176
1.544
1.857
1.973
2.167
2.356
2.492
2.574
2.658
2.793
2.859
2.891
2.910
2.925
2.940
2.951
2.964
2.974
2.988
3.000

0.00
0.33
0.68
1.40
3.19
6.66
9.57
16.56
25.03
32.34
42.12
51.77
62.25
71.04
79.35
87.00
95.79

0.00
0.545
0.855
1.166
1.523
1.842
1.999
2.237
2.417
2.528
2.643
2.732
2.812
2.870
2.918
2.958
3.000

0.00
0.47
0.87
2.24
7.02
14.09
19.04
33.25
44.55
55.38
66.04
71.14
78.38
83.50
88.88
92.59

0.00
0.602
0.954
1.380
1.879
2.260
2.400
2.680
2.760
2.850
2.853
2.888
2.920
2.950
2.990
3.000

0.00
0.34
0.90
2.35
6.86
12.70
18.40
38.25
50.26
63.74
67.89
75.31
83.08
89.66
93.18

0.00
0.562
0.987
1.401
1.760
2.080
2.220
2.613
2.731
2.835
2.862
2.907
2.950
2.983
3.000
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Figure 4. Comparative zero order kinetic plots of different formulations V-1, V-2, V-3, V-4, V-5.
V1 → EC rate controlling membrane
V2 → PVP K30 : EC ; 8:1
V3 → PVP K30 : EC ; 4:1
V4 → PVP K30 : EC ; 2:1
V5 → PVP K30 : EC ; 1:1
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that the curves were fairly linear. Slope values were
computed from the graph. The ‘n’ values suggest that the
films V1 and V2 follow perfect zero order kinetics (n =
1.0) whereas the ocular films V3, V4 and V5 follow a
super case II transport mechanism (n > 1.00), possibly
owing to chain disentanglement and swelling of
hydrophilic polymer. The zero order rate constants, slope
value ‘n’ and their respective ‘r’ values are given in Table
2. Initially it was theorized that incorporating a portion of
hydrophilic polymer PVP K30 into EC might increase the
diffusion of drugs from the HPMC matrix. In this study
we obtained increasing rate constant values (k), which
confirmed our theory. This is probably because the PVP
K30 reduces the resistance offered by the EC film alone,
and by increasing pores and/or their diameter the drug
diffuses with less resistance.

Conclusions

Hence it could be ascertained that a hydrophobic
polymer like EC can be modeled with a hydrophilic
polymer like PVP K30 to release by zero order, limiting
to a proportion, which in this case is proved to be 8:1.
Therefore, to develop potential ocular applications that
can sustain the drug level for several days, EC:PVP K30;
8:1, can be used.

All 6 formulations were found to be smooth,
transparent and flexible. Thickness was fairly uniform as
indicated by their low coefficient of variation. In vitro
release studies revealed that the patches V-1 and V-2
follow perfect zero order kinetics release. Increasing the
amount of PVP K30 in the rate controlling membrane
increases the rate constant ‘k’ and the ocular films V3,
V4, and V5 follow super case-II transport, possibly owing
to chain disentanglement and swelling of hydrophilic

Norfloxacin is a broad-spectrum antibacterial drug
with a half-life of 3.0 to 4.5 h. It is also less soluble in
water. The drug is successfully being used in the
treatment of many eye infections. Therefore, it was
chosen as a model drug for this study. The solubility of
norfloxacin was improved by complexing it with BCD
using a neutralization technique.
In this work, different rate controlling membranes
were prepared from ethyl cellulose alone and in
combination with PVP K30, i.e. 8:1, 4:1, 2:1 and 1:1.
The effect of drug release kinetics was investigated. The
films were evaluated for their thickness. An in vitro study
was carried out in a fabricated open-flow through
assembly.

5
4.5
4
Log Fraction dose

3.5
3
2.5
2
1.5
1
0.5
0
0.000

0.500

1.000
1.500
Log Time
V1

V2

V3

V4

2.000

2.500

V5

Figure 5. Korsemeyer data curves of V1, V2, V3, V4, and V5.
V1 → EC rate controlling membrane
V2 → PVP K30 : EC ; 8:1
V3 → PVP K30 : EC ; 4:1
V4 → PVP K30 : EC ; 2:1
V5 → PVP K30 : EC ; 1:1
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polymer. However, addition of PVP K30 to EC is limited
to 8:1 proportion, to release the drug by zero order. As
the amount of EC is increased, duration of release also
increases without significantly altering the rate of drug
release.
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